Targeting SARS-CoV-2 Polymerase with New Nucleoside Analogues.
Molecules
; 26(11)2021 Jun 07.
Article
in English
| MEDLINE | ID: covidwho-1259549
ABSTRACT
Despite the fact that COVID-19 vaccines are already available on the market, there have not been any effective FDA-approved drugs to treat this disease. There are several already known drugs that through drug repositioning have shown an inhibitory activity against SARS-CoV-2 RNA-dependent RNA polymerase. These drugs are included in the family of nucleoside analogues. In our efforts, we synthesized a group of new nucleoside analogues, which are modified at the sugar moiety that is replaced by a quinazoline entity. Different nucleobase derivatives are used in order to increase the inhibition. Five new nucleoside analogues were evaluated with in vitro assays for targeting polymerase of SARS-CoV-2.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Drug Design
/
Enzyme Inhibitors
/
Coronavirus RNA-Dependent RNA Polymerase
/
SARS-CoV-2
/
Nucleosides
Type of study:
Experimental Studies
Topics:
Vaccines
Language:
English
Journal subject:
Biology
Year:
2021
Document Type:
Article
Affiliation country:
Molecules26113461
Similar
MEDLINE
...
LILACS
LIS